Evidence map›Paper›PMID 39976649›Full record

ArticleGenes & genomics2025

UBE2C regulating the lung carcinoma progression via inhibiting ubiquitin-proteasomal degradation to increase MMP9 protein stability.

Jie Zhao, Juanjuan Dai, Ning Zhou, Dongqin Liu, Dandan Wang, Shuang Miao, Chao Liang, Di An, Jiatong Jiang, Kaikai Gong and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Genes & genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jie Zhao *Department of Oncology, Binzhou Medical University Hospital, Binzhou, People's Republic of China.
Juanjuan Dai *Medical Research Center, Binzhou Medical University Hospital, Binzhou, 256603, People's Republic of China.
Ning ZhouDepartment of Otolaryngology Head and Neck Surgery, Binzhou Medical University Hospital, Binzhou, 256603, People's Republic of China.
Dongqin LiuDepartment of Gastroenterology, Binzhou People's Hospital, Binzhou, 256603, People's Republic of China.
Dandan WangDepartment of Oncology, Binzhou Medical University Hospital, Binzhou, People's Republic of China.
Shuang MiaoMedical Research Center, Binzhou Medical University Hospital, Binzhou, 256603, People's Republic of China.
Chao LiangDepartment of Oncology, Binzhou Medical University Hospital, Binzhou, People's Republic of China.
Di AnDepartment of Oncology, Binzhou Medical University Hospital, Binzhou, People's Republic of China.
Jiatong JiangDepartment of Oncology, Binzhou Medical University Hospital, Binzhou, People's Republic of China.
Kaikai GongDepartment of Oncology, Binzhou Medical University Hospital, Binzhou, People's Republic of China. gongkaikai1005@bzmc.edu.cn.
Yan WuDepartment of Oncology, Binzhou Medical University Hospital, Binzhou, People's Republic of China. wuyan55@bzmc.edu.cn.ORCID 0000-0003-1434-9361

Funding

Natural Science Foundation of Shandong Province ZR2023MH126Shandong Provincial Pharmaceutical Technology Development Plan 202202080906
6 · The paper itself

Abstract

backgroundNon-small-cell-lung-cancer (NSCLC) is a prevalent lung malignancy among humans. UBE2C is a critical component of the ubiquitin-proteasome system, and its expression level is significantly associated with cancer development and cell proliferation. Nevertheless, the mechanisms of UBE2C in NSCLC remain unclear.

objectiveWe aimed to investigate the role of MMP9 in UBE2C-overexpressed NSCLC progression.

methodsThe GEPIA database and Kaplan-Meier curves were used to determine UBE2C expression in human tumors and survival in NSCLC. CCK8, colony formation, and Transwell

resultsThis research proved that UBE2C expression was related to patient overall survival, cell proliferation and migration. Furthermore, overexpressed UBE2C could promote the protein stability of Matrix metalloproteinase-9 (MMP9) to upregulate its protein level in NSCLC cells. Meanwhile, UBE2C upregulation promoted lung carcinoma progression by modulating MMP9 expression.

conclusionsOur findings indicate that UBE2C may be a therapeutic and prognostic target for lung carcinoma.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMatrix Metalloproteinase 9UbiquitinUbiquitin-Conjugating EnzymesCell Line, TumorCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansProteasome Endopeptidase ComplexProtein StabilityMatrix Metalloproteinase 9MMP9 protein, humanProteasome Endopeptidase ComplexUBE2C protein, humanUbiquitinUbiquitin-Conjugating EnzymesLung carcinomaMigrationMMP9UBE2C

Identifiers

PMID39976649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.